TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01693185
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion 0.4 mcg/kg/min
Study: NCT01693185
Drug: placebo (for meperidine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline mimic meperidine injection
Study: NCT01401543
Drug: LY2452473
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00897871
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01636089
Drug: bicarbonates
Normalized name: BICARBONATES
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium bicarbonates 1,4%
Study: NCT00003974
Drug: DetoxPC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003974
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003974
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01887288
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m\^2 PO b.i.d.
Study: NCT00556257
Drug: CP-690-,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
Study: NCT01717157
Drug: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
Study: NCT02915250
Drug: Humalog® Mix25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Humalog® Mix25
Study: NCT02915250
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Lantus®
Study: NCT00039481
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00039481
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00370435
Drug: GW274150
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178358
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02178358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00479115
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
Study: NCT00264290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo designed to resemble Valganciclovir
Study: NCT02779075
Drug: Exendin-9,39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
Study: NCT00914498
Drug: Local, pre-incisional injection of 20 ml 1% xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local, pre-incisional injection of 20 ml 1% xylocaine
Study: NCT04362501
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo SC injection every two weeks for six months
Study: NCT00408187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00057005
Drug: CAMPATH-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-8 through Day-6 according to institutional SOPs
Study: NCT00057005
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day-7 through Day-6 45 mg/kg
Study: NCT00391807
Drug: Norethindrone acetate/ethinyl estradiol
Normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet per day
Study: NCT01110226
Drug: KML-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.
Study: NCT02574819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Study: NCT01917695
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
Study: NCT05103306
Drug: INS
Normalized name: mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal insulin add on the background OADs
Study: NCT00497341
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
Study: NCT03714776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching solution administered as SC injection.
Study: NCT00404833
Drug: prednisolone and mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04306393
Drug: Nitric Oxide Gas
Normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively.
Study: NCT00583011
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group: 2cc Normal Saline
Study: NCT03315494
Drug: SKI-O-703 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKI-O-703 200 mg capsule with no inactive excipients.
Study: NCT03315494
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 180 mg capsule filled with microcrystalline cellulose.
Study: NCT03838029
Drug: Propranolol and etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A perioperative combined drug regimen
Study: NCT00134758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day
Study: NCT02394015
Drug: Trabectedin and Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
Study: NCT02629042
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
Study: NCT04281628
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
Study: NCT03610880
Drug: TG-2349 (400 mg) plus DAG181 (200 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Study: NCT03610880
Drug: DAG181 (200 mg) plus TG-2349 (400 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
Study: NCT00777062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection at the start of weeks 2 and 6.
Study: NCT00652808
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Study: NCT00652808
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study: NCT00080483
Drug: Testosterone plus somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
Study: NCT00080483
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AndroGel transdermally 5 g a day for two years
Study: NCT02469012
Drug: Combination #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir + Ribavirin
Study: NCT02469012
Drug: Combination #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir + Daclatasvir
Study: NCT02469012
Drug: Combination #3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir + Daclatasvir + Ribavirin
Study: NCT02469012
Drug: Combination #4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir + Ledipasvir
Study: NCT02469012
Drug: Combination #5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir + Ledipasvir + Ribavirin
Study: NCT02900664
Drug: TMT212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT02900664
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03762681
Drug: RO7239958
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, subcutaneous use (SC).
Study: NCT02373137
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
Study: NCT01119846
Drug: GSK1292263
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
Study: NCT01119846
Drug: GSK1292263 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to active drug GSK1292263
Study: NCT02559570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study: NCT02559570
Drug: LIN Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study: NCT02559570
Drug: LIN Dose C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study: NCT02383355
Drug: Continuation of own regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation of own antiretroviral medication during the 10 weeks follow-up
Study: NCT02766036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
Study: NCT00001338
Drug: FLAC chemotherapy with GM-CSF
Normalized name: Flac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01219192
Drug: M2ES 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES 60mg IV D1,8,15,22 every 28days a cycle
Study: NCT00736294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
Study: NCT03279601
Drug: Capecitabine, Dacarbazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
Study: NCT03279601
Drug: Capecitabine, Temozolomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
Study: NCT02320448
Drug: PIPAC
Normalized name: Zagam Respipac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182830
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting dose 10mg; forced titration after 4 weeks 25mg dose
Study: NCT02348008
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
Study: NCT02348008
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Phase II Treatment: 200mg IV
Study: NCT02453256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
Study: NCT02370550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 2-3 mg/kg/d, BID PO
Study: NCT02370550
Drug: Calcium carbonate D
Normalized name: calcium carbonate / cholecalciferol Oral Tablet [Oysco D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbonate D 600 mg, QD PO
Study: NCT02822157
Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: physician's choice chemotherapy
Study: NCT03816618
Drug: Hydrogel
Normalized name: HYDROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PURLOIN GEL
Study: NCT03685500
Drug: Symtuza® (TAF/FTC/DRV/c)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
Study: NCT03685500
Drug: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
Study: NCT02603510
Drug: SAR342434
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT05204758
Drug: TCM Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: three packages of TCM preparations with each meal three times a day
Study: NCT00228410
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02688764
Drug: Calcium Acetate (Phoslyra®)
Normalized name: calcium acetate Oral Solution [Phoslyra]
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.
Study: NCT02829502
Drug: Normosaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of subcutaneous injection of 20 μL normosaline (placebo).
Study: NCT01709409
Drug: BLES-group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 3 doses are administered to infants with RDS
Study: NCT01306214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 low dose
Study: NCT01306214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 high dose
Study: NCT00219219
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03440970
Drug: Lysine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the study drug twice a day for 5 days.
Study: NCT01359020
Drug: ibuprofen, dipyrone, acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
Study: NCT00864305
Drug: NEURONTIN® 400 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis's marketed product
Study: NCT03059537
Drug: Oral chenodeoxycholic acid stimulation
Normalized name: chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
Study: NCT03188523
Drug: MK-8504
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
Study: NCT00968708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo matching tablets
Study: NCT01170949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01031199
Drug: F-18 FEDAA1106 (BAY85-8101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Study: NCT02678728
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
Study: NCT02186158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02372383
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-mycobacterial oral drug
Study: NCT00329095
Drug: Additional ocular hypotensive medication
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00392756
Drug: gonadotropin releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
Study: NCT03675971
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02709109
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02709109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04605718
Drug: RO7223280
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
Study: NCT02483455
Drug: 2014-ALC-919-US
Normalized name: Drugs used in alcohol dependence
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical solution to be applied twice daily for the treatment of Common Warts
Study: NCT00259038
Drug: Carperitide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00259038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00888797
Drug: Propranolol and Etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
Study: NCT04755894
Drug: HDDO-1756
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01462656
Drug: Non-EZG AED monotherapy
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: AED monotherapy without EZG
Study: NCT01679028
Drug: T89 Group B
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg single dose
Study: NCT03928379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01505231
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study: NCT01690299
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets BID
Study: NCT01690299
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Study: NCT00201318
Drug: Cyclophosphamide Doxorubicin Vincristine Lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01556932
Drug: ABH gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given topically
Study: NCT02710552
Drug: Tripliam (perindopril, indapamide, amlodipine)
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
Study: NCT00776009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00323076
Drug: 18F-FAZA PET Imaging
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient.